Pharmacogenetics may play a key role in individualizing anthracycline dosing to mitigate the risk of cardiotoxicity in cancer survivors.
Answers are grounded in this paper and cite their sources.
Genetic variants may influence anthracycline cardiotoxicity risk in survivors; leaves open genotype-guided strategies pending validation.
Anthracyclines constitute a fundamental part of the chemotherapy regimens utilized to treat a number of different malignancies both in pediatric and adult patients. These drugs are one of the most efficacious anticancer agents ever invented. On the other hand, anthracyclines are cardiotoxic. Childhood cancer survivors treated with anthracyclines often undergo cardiac complications which are influenced by genetic variations of the patients. The scientific literature comprises numerous investigations in the subject of the pharmacogenetics of anthracyclines. In this review, we provide a comprehensive overview of this research topic. Genetic variants are proposed targets in the personalized treatment in order to individualize dosing and therefore reduce side effects.
No takes yet. Share an insight, caveat, or question.
Sági et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: